The chronic effects of triacylglycerol structure of palm oil on glucose homeostasis, insulin secretion and sensitivity and lipid metabolism

Completed

Conditions: Cardiovascular disease
Circulatory System
Ischaemic heart diseases

Registration Number: ISRCTN16669399

Lead Sponsor: King's College London (UK)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 54

Inclusion Criteria

Healthy male and female participants, aged between 20 and 50 years

Exclusion Criteria

1. Medical history of myocardial infarction, angina, thrombosis, stroke, cancer or diabetes
2. Participants with metabolic syndrome as defined by the International Diabetes Federation (http://www.idf.org/webdata/docs/MetS_def_update2006.pdf)
3. Underweight [Body mass index (BMI) < 18.5 kg/m2] or obese (BMI = 30 kg/m2)
4. Plasma cholesterol > 7.0 mmol /L
5. Plasma triacylglycerol > 3 mmol /L
6. Plasma glucose > 7 mmol /L
7. Current use of antihypertensive, lipid lowering, insulin/glucose-modulating medication
8. Alcohol intake exceeding a moderate intake (> 21 units/week for males and > 14 units/week for females)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. ß-cell function (measured as the increments in C-peptide response to a mixed meal) will be measured at fasting, 10, 20, 30, 60, 90 and 120 minutes postprandially. These measurements will be taken at the baseline visit, 6, 12 and 18 week visits. <br>2. C-peptide will also be measured at fasting at the 3, 9 and 15 week visits. C-peptide will be measured using a solid-phase, two-site chemiluminescence immunoassay

Secondary Outcome Measures

Name	Time	Method
1. Insulin and glucose concentrations will be measured at fasting (in duplicate separated by a 5-minute interval), 10, 20, 30, 60, 90 and 120 minutes postprandially at the baseline visit, 6, 12 and 18 week visits.<br>2. Insulin and glucose concentrations will also be measured at fasting (in duplicate as described above) at the 3, 9 and 15 week visits. Insulin will be measured using a solid phase, two-site chemiluminescence immunoassay and glucose will be measured using an endpoint enzymatic reaction.